In the Spotlight June 2004

A structured, risk-based framework for pharmaceutical compounding that enhances quality, regulatory compliance, and process consistency.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

An ordered pharmaceutical compounding process for use in 503A pharmacies, 503B outsourcing facilities, pharmaceutical industry, and other applications.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The partnership was formed in September 2024 in response to increasing demand for aseptic filling technologies and processes.

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.